Innovative care model for patients with complex muscle diseases

Current Opinion in Neurology

Volumn 27, Issue 5, 2014, Pages 607-613

  Quinlivan, Ros ^a,b   Matthews, Emma ^a   Hanna, Michael G ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

Duchenne muscular dystrophy; Muscular dystrophy; Neuromuscular Complex Care Centre; Neuromuscular models of care; Survival

Indexed keywords

CORTICOSTEROID;

CONSENSUS; CORTICOSTEROID THERAPY; DUCHENNE MUSCULAR DYSTROPHY; EMERGENCY CARE; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE NEED; HEALTH CARE QUALITY; HOLISTIC CARE; HOME CARE; HOSPITAL ADMISSION; HOSPITAL PERSONNEL; HUMAN; INTERPERSONAL COMMUNICATION; LIFE EXPECTANCY; MEDICAL AUDIT; MEDICAL SPECIALIST; NEUROMUSCULAR DISEASE; NONINVASIVE VENTILATION; PATIENT CARE; PATIENT SAFETY; PRACTICE GUIDELINE; REHABILITATION CARE; REVIEW; TOTAL QUALITY MANAGEMENT; TRANSITION TO ADULT CARE; COST BENEFIT ANALYSIS; MUSCLE DISEASE; NURSING;

COST-BENEFIT ANALYSIS; HUMANS; MUSCULAR DISEASES; PATIENT CARE;

EID: 84925719332     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0000000000000132     Document Type: Review

References (32)

1. Emery AE. Population frequencies of inherited neuromuscular diseases - a world survey. Neuromuscul Disord 1991;1:19-29.
2. Norwood FM, Harling C, Chinnery PF, et al. Prevalence of genetic muscle disease in Northern England: in depth analysis of a muscle clinic population. Brain 2009;132:3175-3185.
3. Hill ME, Phillips MF. Service provision for adults with long-term disability: a review of services for adults with chronic neuromuscular conditions in the United Kingdom. Neuromuscul Disord 2006;16:107-112.
4. Muscular Dystrophy Campaign Report: The State of the Nation: National Patient Survey; January 2013.
5. Nijman JL, Groenen AMR, Horemans AMC, Delnoij DMJ. Quality of hospital care for neuromuscular disorders from the patients' perspective. Neuromuscul Disord 2013;23:279-282. This article highlights problems associated with poor communication between hospital and community teams. Patients who were surveyed recognized healthcare to be better overall when provided in a specialized centre, but even then it was not described as excellent. The authors propose centralizing adult neuromuscular care to a few Specialist Centres where expertise can be developed.
6. Scully MA, Cwik VA, Marshall BC, et al. Can outcomes in Duchenne muscular dystrophy be improved by public reporting of data? Neurology 2013;80:583-589. This short article describes variations in care across health regions in the USA and makes a recommendation for all centres to report their outcomes. It suggests that published guidelines are not being universally followed and makes an analogy with the situation for adults with CF in the early 1990s.
7. DMD Care Considerations Working Group. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy Part 1. Lancet Neurol 2010;9:77-93.
8. DMD Care Considerations Working Group. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 2010;9:177-189.
9. NICE Guidelines, Motor neurone disease: the use of noninvasive ventilation in the management of motor neurone disease; July 2010.
10. Wang CH, Finkel RS, Bertini ES, et al. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol 2007;22:1027-1049.
11. Wang CH, Bonnemann CG, Rutkowski A, et al. Consensus statement on standard of care for congenital muscular dystrophies. J Child Neurol 2010;25:1559-1581.
12. Schram G, Fournier A, Leduc H, et al. All-cause mortality and cardiovascular outcomes with prophylactic steroid therapy in Duchenne muscular dystrophy. J Am Coll Cardiol 2013;61:948-954. This study demonstrates cardiac follow-up data for boys with DMD on long-term steroid treatment and demonstrates a significant cardio-protective effect with delayed onset of cardiomyopathy.
13. Martigne L, Seguy D, Pellegrini N, et al. Efficacy and tolerance of gastrostomy feeding in Duchenne muscular dystrophy. Clin Nutr 2010;29:60-64.
14. Van Den Engel-Hoek L, Erasmus CE, Hendriks JC, et al. Oral muscles are progressively affected in Duchenne muscular dystrophy: implications for dysphagia treatment. J Neurol 2013;260:1295-1303.
15. Askeland EJ, Arlen AM, Erickson BA, et al. Urological manifestations of Duchenne muscular dystrophy. J Urol 2013;190(Suppl 4):1523-1528.
16. Eagle M, Baudouin SV, Chandler C, et al. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord 2002;12:926-929.
17. Eagle M, Bourke J, Bullock R, et al. Managing Duchenne muscular dystrophy - the additive effect of spinal surgery and home nocturnal ventilation in improving survival. Neuromuscul Disord 2007;17:470-475.
18. Ishikawa Y, Miura T, Ishikawa Y, et al. Duchenne muscular dystrophy: survival by cardio-respiratory interventions. Neuromuscul Disord 2011;21:47-51.
19. Jeppesen J, Green A, Steffensen BF, Rahbek J. The Duchenne muscular dystrophy population in Denmark, 1997-2001: prevalence, incidence and survival in relation to the introduction of ventilator use. Neuromuscul Disord 2003;13:804-812.
20. American Thoracic Society. Finder JD, Birnkrant D, Carl J, et al. Respiratory care of the patient with Duchenne muscular dystrophy: ATS consensus statement. Am J Respir Crit Care Med 2004;170:456-465.
21. McDougall CM, Adderley RJ, Wensley DF, Seear MD. Long-term ventilation in children: longitudinal trends and outcomes. Arch Dis Child 2013;98:660-665. This article reviews the outcome data for children treated with noninvasive ventilation over the past 15 years in Canada. Data demonstrate excellent longterm survival with noninvasive ventilation being marginally better than invasive ventilation. It demonstrates the rapid growth of a 'new' population of survivors being transitioned to adult services. In his editorial in the same Journal, Robert Graham warns of an impending crisis for unprepared adult services.
22. Graham RJ. Long-term ventilation: charting a pathway home. Arch Dis Child 2013;98:653. This editorial raises concern for the future health service burden of growing numbers of children on long term ventilation surviving to adulthood and calls for a major 're-think' in how service delivery models are provided.
23. Schrans DGM, Abbott D, Peay HL, et al. Transition in Duchenne muscular dystrophy: an expert meeting report and description of transition needs in an emergent patient population (Parent Project Muscular Dystrophy Transition Expert Meeting 17-18 June 2011, Amsterdam, The Netherlands). Neuromuscul Disord 2013;23:283-286.
24. Jaffer F, Reilly MM, Quinlivan R, et al. Emergency neuromuscular admissions are avoidable: a regional audit of unplanned hospital admissions of neuromuscular patients 2009-2011: final results and recommendations. J Neurol Neurosurg Psychiatry 2013;84:e2.
25. Schechter MS, Gutierrez HH. Improving the quality of care for patients with cystic fibrosis. Curr Opin Pediatr 2010;22:296-301.
26. Phelan P, Hey E. Cystic fibrosis mortality in England and Wales and in Victoria, Australia 1976-80. Arch Dis Child 1984;59:71-73.
27. Walters S, Britton J, Hodson ME. Hospital care for adults with cystic fibrosis: an overview and comparison between special cystic fibrosis clinics and general clinics using a patient questionnaire. Thorax 1994;49:300-306.
28. Cystic fibrosis in adults. Recommendations for care of patients in the UK. Summary of a report of The Royal College of Physicians. J R Coll Physicians Lond 1991;25:12-15.
29. Hodson ME. Treatment of cystic fibrosis in the adult. Respiration 2000;67:595-607.
30. Mahadeva R, Webb K, Westerbeek RC, et al. Clinical outcome in relation to care in centres specialising in cystic fibrosis: cross sectional study. BMJ 1998;316:1771-1775.
31. Smith M. Efficacy of specialist versus nonspecialist management of spinal cord injury within the UK. Spinal Cord 2002;40:10-16.
32. Landfeldt E, Lindgren P, Bell C, et al. The burden of Duchenne muscular dystrophy: an international, cross-sectional study. Neurology 2014. [Epub ahead of print] This study was designed to estimate the total cost of illness and economic burden of DMD. Patients from Italy, United Kingdom, Germany and USA were included (770 in total), direct medical costs included hospital and physiotherapy appointments, tests and assessments, specialist physicians, medication, aids and devices which had an annual cost of $23 920-54 270. This cost was greatest for patients in the late nonambulant stage of the condition.